Discovery and Identification
The story of alpha-lipoic acid begins in 1937, when Esmond Emerson Snell and colleagues identified a bacterial growth factor in potato extract that was required for the growth of certain microorganisms. This unknown factor was designated the**"potato growth factor"** and later the**"pyruvate oxidation factor,"** reflecting its role in oxidative metabolism.
Isolation and Characterization
In 1951,Lester J. Reed and colleagues at the University of Texas at Austin achieved the landmark isolation and structural characterization of this factor, requiring10 tons of beef liver residue to obtain just 30 milligrams of the pure compound. Reed named italpha-lipoic acid (from the Greek "lipos" meaning fat, reflecting its lipid solubility) and determined its structure as a cyclic disulfide — a five-membered dithiolane ring attached to a valeric acid chain. This identification was a triumph of mid-century biochemistry and earned Reed international recognition.
Role in Mitochondrial Metabolism
Throughout the 1950s and 1960s, Reed and other researchers established ALA's role as an essential cofactor for the pyruvate dehydrogenase and alpha-ketoglutarate dehydrogenase enzyme complexes — critical enzymes that link glycolysis to the citric acid cycle, forming the foundation of aerobic energy production in all eukaryotic cells.
Clinical Use in Diabetic Neuropathy
In 1966, alpha-lipoic acid wasapproved in Germany for the treatment of diabetic peripheral neuropathy under the brand nameThioctacid (manufactured by MEDA/Viatris). Germany has the longest clinical track record with ALA for this indication, with large-scale trials including the ALADIN (Alpha-Lipoic Acid in Diabetic Neuropathy) series demonstrating significant improvement in neuropathic symptoms with intravenous and oral ALA. ALA remains a first-line treatment for diabetic neuropathy in German clinical practice.
The Universal Antioxidant
In the 1990s,Lester Packer at the University of California, Berkeley, championed ALA as the**"universal antioxidant"** — coining the term to describe ALA's unique ability to function in both aqueous and lipid environments and to regenerate other antioxidants (vitamins C and E, glutathione, CoQ10). Packer's research and advocacy significantly elevated ALA's profile in the antioxidant supplement market and in academic antioxidant research.
The Andy Cutler Protocol
In the late 1990s-2000s,Andrew Hall Cutler, PhD (a Princeton-educated chemist), developed a protocol for mercury detoxification using frequent, low-dose ALA chelation. Cutler, who attributed his own chronic health issues to mercury exposure from dental amalgams, published**"Amalgam Illness: Diagnosis and Treatment"** (1999) and built a substantial following in autism, chronic fatigue, and chronic illness communities. The Cutler Protocol emphasizes taking ALA every 3 hours around the clock (to maintain steady chelation without redistribution) in rounds of 3+ days followed by rest periods, starting at very low doses (12.5-25mg) and increasing gradually. Despite limited formal clinical validation, the protocol has thousands of adherents worldwide and has spawned dedicated online communities.
Modern Supplement Market
By the 2010s and 2020s, alpha-lipoic acid had become one of the most widely sold antioxidant supplements globally, available in racemic and R-ALA forms, with applications marketed for:
- Antioxidant and anti-aging support
- Blood sugar management and insulin sensitivity
- Neuroprotection and cognitive support
- Heavy metal detoxification
- Weight management (via AMPK activation)
- Skin health and anti-aging (topical formulations)
Annual global ALA supplement sales now exceed hundreds of millions of dollars, with growth driven by the expanding diabetic population, growing awareness of environmental toxin exposure, and the broader antioxidant supplement trend.
